Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J.P. Morgan Notebook Day 1: Pfizer, Gilead, Alnylam, Novartis, Sarepta, Deal Trends And Cell Therapy Challenges

Executive Summary

News and notes from the 2019 J.P. Morgan Healthcare Conference. Pfizer CEO Bourla underscores need for scientific and commercial innovation, Gilead makes M&A a priority, Novartis' new R&D chief reflects on first meeting with CEO Narasimhan, Sarepta CEO Ingram clarifies regulatory path for micro-dystrophin, J.P. Morgan outlines deal and macro biopharma trends in 2019, and cell therapy panel discusses manufacturing challenges.

Advertisement

Related Content

US FDA's New Development Science Office Modeled On Modeling Office
Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?
US Drug Pricing: What A Difference A Year Makes
The Case For CAR-T Grows As Responses Hold Up Longer Term
CEO of New UK Cell And Gene Therapy Hub Says 'All Systems Are Go'
Deal Watch: Genentech Gets Down In The Dirt With Lodo Therapeutics
Appointments: Novartis And GSK Announce New R&D Heads, LNC Therapeutics Gets A New CEO, Plus Announcements From Zelluna and BC Platforms
Iovance Biotherapeutics CEO On TIL Immunotherapy For Solid Tumors
Autolus Raises $80m To Take T-Cell Engineering To The Next Level

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124514

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel